References

AAAS (American Association for the Advancement of Science). 2009. Programs, Science and Policy, R&D Budget and Policy Program. http://www.aaas.org/spp/rd/guitotal.htm (accessed September 3, 2010).

AAP (American Academy of Pediatrics) Medical Home Initiatives for Children with Special Needs Project Advisory Committee. 2002. The medical home. Pediatrics 110(1): 184-186.

Abernethy, A. P., G. Raman, E. M. Balk, J. M. Hammond, L. A. Orlando, J. L. Wheeler, J. Lau, and D. C. McCrory. 2009. Systematic review: reliability of compendia methods for off-label oncology indications. Annals of Internal Medicine 150(5):336-343.

AbioMed, Inc. 2005. ABIOMED Announces Increased Reimbursement from CMS for Successful Recovery of the Native Heart (press release). http://www.abiomed.com/news/CMS_Reimbursement.cfm (accessed August 10, 2010).

AbioMed, Inc. 2009. Form 10-Q. http://www.faqs.org/sec-filings/091106/ABIOMED-INC_10-Q/ (accessed August 10, 2010).

ACP (American College of Physicians). 2004. Patient-Centered, Physician-Guided Care for the Chronically Ill: The American College of Physicians Prescription for Change. Philadelphia, PA: American College of Physicians.

ACR (American College of Rheumatology). 2010. Summary of January 21 Teleconference with FDA Regarding Colchicine. http://www.rheumatology.org/advocacy/colchicine_fda.pdf (accessed August 10, 2010).

ACS (American Cancer Society). 2010. Clinical Trials: State Laws Regarding Insurance Coverage. http://www.cancer.org/docroot/ETO/content/ETO_6_2x_State_Laws_Regarding_Clinical_Trials.asp (accessed August 10, 2010).

Adams, J. U. 2008. Imprinting and genetic disease: Angelman, Prader-Willi, and Beckwith-Wiedemann syndromes. Nature Education 1(1). http://www.nature.com/scitable/topicpage/imprinting-and-genetic-disease-angelman-prader-willi-923 (accessed September 24, 2010).

AdvaMed (Advanced Medical Technology Association). 2004. Future Trends in Medical Device Innovation. http://www.advamed.org/MemberPortal/About/NewsRoom/MediaKits/futuretrendsinmedicaldeviceinnovaton.htm (accessed August 10, 2010).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 249
References AAAS (American Association for the Advancement of Science). 2009. Programs, Science and Policy, R&D Budget and Policy Program. http://www.aaas.org/spp/rd/guitotal.htm (ac- cessed September 3, 2010). AAP (American Academy of Pediatrics) Medical Home Initiatives for Children with Spe- cial Needs Project Advisory Committee. 2002. The medical home. Pediatrics 110(1): 184-186. Abernethy, A. P., G. Raman, E. M. Balk, J. M. Hammond, L. A. Orlando, J. L. Wheeler, J. Lau, and D. C. McCrory. 2009. Systematic review: reliability of compendia methods for off-label oncology indications. Annals of Internal Medicine 150(5):336-343. AbioMed, Inc. 2005. ABIOMED Announces Increased Reimbursement from CMS for Suc- cessful Recovery of the Native Heart (press release). http://www.abiomed.com/news/ CMS_Reimbursement.cfm (accessed August 10, 2010). AbioMed, Inc. 2009. Form 0-Q. http://www.faqs.org/sec-filings/091106/ABIOMED-INC_10- Q/ (accessed August 10, 2010). ACP (American College of Physicians). 2004. Patient-Centered, Physician-Guided Care for the Chronically Ill: The American College of Physicians Prescription for Change. Phila- delphia, PA: American College of Physicians. ACR (American College of Rheumatology). 2010. Summary of January  Teleconference with FDA Regarding Colchicine. http://www.rheumatology.org/advocacy/colchicine_fda. pdf (accessed August 10, 2010). ACS (American Cancer Society). 2010. Clinical Trials: State Laws Regarding Insurance Coverage. http://www.cancer.org/docroot/ETO/content/ETO_6_2x_State_Laws_Regard ing_Clinical_Trials.asp (accessed August 10, 2010). Adams, J. U. 2008. Imprinting and genetic disease: Angelman, Prader-Willi, and Beckwith- Wiedemann syndromes. Nature Education 1(1). http://www.nature.com/scitable/topic page/imprinting-and-genetic-disease-angelman-prader-willi-923 (accessed September 24, 2010). AdvaMed (Advanced Medical Technology Association). 2004. Future Trends in Medical Device Innovation. http://www.advamed.org/MemberPortal/About/NewsRoom/Media Kits/futuretrendsinmedicaldeviceinnovaton.htm (accessed August 10, 2010). 

OCR for page 249
0 RARE DISEASES AND ORPHAN PRODUCTS AdvaMed. 2009. Statement Presented by Susan Alpert to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23. Aetna. 2010. Clinical Policy Bulletin: Heart Transplantation. http://www.aetna.com/cpb/ medical/data/500_599/0586.html (accessed August 10, 2010). AIMBE (American Institute for Medical and Biological Engineering). 2005. AIMBE Hall of Fame salutes PET as one of 24 achievements in medical, biological engineering. Molecu- lar Imaging News, March 10. Aiuti, A., I. Brigida, F. Ferrua, B. Cappelli, R. Chiesa, S. Marktel, and M. Roncarolo. 2009. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. Immu- nologic Research 44(1-3):150-159. Alliance for a Stronger FDA. 2009. Written Statement of the Alliance for a Stronger FDA, U.S. Food and Drug Administration Regarding FY0 Appropriations for the U.S. Food and Drug Administration Submitted to the Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, U.S. Sen- ate, March , 00. http://fdaalliance.files.wordpress.com/2009/11/alliance-statement- senate-appropriations-committee-fy-11.doc (accessed August 10, 2010). Anand, G. 2005. How drugs for rare diseases became lifeline for companies. Wall Street Journal, November 15. http://online.wsj.com/article/SB113202332063297223.html (ac- cessed August 10, 2010). Anderson, T. 2009. Novartis under fire for accepting new reward for old drug. Lancet 373(9673):1414. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09) 60804-7/fulltext (accessed August 24, 2010). Anglim, P. P., T. A. Alonzo, and I. A. Laird-Offringa. 2008. DNA methylation-based bio- markers for early detection of non-small cell lung cancer: an update. Molecular Cancer 7(81). Ariyanchira, S. 2008. BioMarket trends: orphan drug arena driven by biologics. Genetic Engineering and Biotechnology News 21(1). http://www.genengnews.com/gen-articles/ biomarket-trends-orphan-drug-arena-driven-by-biologics/2318/ (accessed August 10, 2010). Arnon, S. S. 2007. Creation and development of the public service orphan drug human botu- lism immune globulin. Pediatrics 119(4):785-789. http://www.cdph.ca.gov/programs/ ibtpp/Documents/Peds-Creatn-Devlpmt-BIG-IV-2007.pdf (accessed August 10, 2010). Asamoah, A. K., and J. M. Sharfstein. 2010. Transparency at the Food and Drug Administra- tion. New England Journal of Medicine 362:25. http://www.nejm.org/doi/pdf/10.1056/ NEJMp1005202 (accessed August 20, 2010). Asbury, C. H. 1985. Orphan Drugs, Medical Versus Market Value. Lexington, MA: Lexington Books. Asbury, C. H. 1991. The Orphan Drug Act: the first 7 years. Journal of the American Medical Association 265(7):893-897. ASH (American Society of Hematology). 2007. Toward a New Research Paradigm: Building a New Sickle Cell Disease Research Agenda. http://www.hematology.org/Advocacy/Policy- Statements/2680.aspx (accessed August 10, 2010). Ashlock, M. 2010. Increasing the therapeutic options for individuals with rare diseases. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 23. ASHP (American Society of Health-System Pharmacists). 2010. Manufacturer PAPs. http:// www.ashp.org/Import/PRACTICEANDPOLICY/PracticeResourceCenters/Patient AssistancePrograms/ManufacturerPAPs.aspx (accessed August 10, 2010). Atkins, D., J. Siegel, and J. Slutsky. 2005. Making policy when the evidence is in dispute. Health Affairs 24(1):102-113.

OCR for page 249
 REFERENCES Austin, C. P. 2010. NIH translational research for rare diseases and orphan products: NCGC and TRND. Presentation to the IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4. Australia. 1989. Therapeutic Goods Act. http://www.comlaw.gov.au/ComLaw/Legislation/ ActCompilation1.nsf/0/840CB0162B421D54CA256FBF00121547/$file/Therapeutic Goods1989_WD02.pdf (accessed August 10, 2010). Australian Bureau of Statistics. 2008. 0.0..00 Australian Historical Population Statistics. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3105.0.65.0012008? OpenDocument (accessed August 10, 2010). Aylward, E. H. 2007. Change in MRI striatal volumes as a biomarker in preclinical Hunting- ton’s disease. Brain Research Bulletin 72(2-3):152-158. Aymé, S. 2009. From ICD10 to ICD11: proposal for a general approach and incorporation of rare diseases. Presentation to the Committee for Orphan Medicinal Products (COMP), European Medicines Agency, London. April 9. http://www.eurordis.org/IMG/pdf/ICD_ revision_S_Ayme_EMEA_March_09.pdf (accessed August 10, 2010). Azuma, H., N. Paulk, A. Ranade, C. Dorrell, M. Al-Dhalimy, E. Ellis, S. Strom, et al. 2007. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nature Biotech- nology 25(8):903-910. http://kaylab.stanford.edu/manuscripts/NBT07Azuma.pdf (ac- cessed August 10, 2010). Baily, M. A., and T. H. Murray. 2008. Ethics, evidence, and cost in newborn screening. Hast- ings Center Report 38(3):23-31. http://www.thehastingscenter.org/uploadedFiles/Publi cations/HCR/Articles/2008_May-June/hcr_2008_may_jun_early_release1.pdf (accessed August 10, 2010). Bainbridge J. W. B., A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, et al. 2008. Effect of gene therapy on visual function in Leber’s congenital amaurosis. New England Journal of Medicine 358:2231-2239. Beitz, J. 2006. Approval letter to Genzyme Corporation for BLA 125141/0 [Alglucosidease alfa/Myozyme]. April 28. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/ 125141s0_LTR.pdf (accessed August 24, 2010). Beitz, J. 2010. Approval letter to Orphan Europe for NDA 022562 [Carbaglu]. March 18. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022562s000ltr.pdf (ac- cessed August 19, 2010). Bellingham, M. C. 2010. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neuroscience & Therapeutics March 10 [e-pub ahead of print]. Benderly, B. L. 2009. The End of Blinding Trachoma Among The World’s Poor Is in Sight. http://www.dcp2.org/features/75 (accessed August 10, 2010). Benson, D.A., I. Karsch-Mizrachi, D. J. Lipman, J. Ostell, and D. L.Wheeler. 2008. GenBank. Nucleic Acids Research 36 (Database issue):D25-30. Berger, E. 2009. Medicare’s Inpatient New Technology Add-on: The Trials of InfraReDx, the Triumph of Spiration. http://larchmontstrategic.blogspot.com/2009/08/medicares- inpatient-new-technology-add.html (accessed August 10, 2010). Bernad, D. M. 2009. Humanitarian use device and humanitarian device exemption regulatory programs: pros and cons. Expert Reviews 6(2):137-145. Berry, D. A. 2006. A guide to drug discovery: Bayesian clinical trials. Nature Reviews 5:27-36. Beutler, E., T. Gelbart, P. Lee, R. Trevino, M. A. Fernandez, and V. F. Fairbanks. 2000. Mo- Mo- lecular characterization of a case of atransferrinemia. Blood 96(13):4071-4074. Billiondollarwoman. 2010. Comment on: The World’s Most Expensive Drugs. http://rate. forbes.com/comments/CommentServlet?op=cpage&sourcename=story&StoryURI=2010/ 02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html (accessed August 10, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS Bonabeau, E., N. Bodick, and R. W. Armstrong. 2008. A more rational approach to new product development. Harvard Business Review, March. http://people.icoserver.com/ users/eric/hbr_NPD.pdf (accessed August 10, 2010). Boodman, S. G. 2009. Annoying bug turned out to be much more. Washington Post, November 3. http://www.washingtonpost.com/wp-dyn/content/article/2009/11/02/ AR2009110202432.html (accessed August 10, 2010). Booz Allen Hamilton Inc. 2008. Independent Evaluation of FDA’s First Cycle Review Perfor- mance: Final Report. http://www.fda.gov/downloads/ForIndustry/UserFees/Prescription DrugUserFee/ucm127982.pdf (accessed August 10, 2010). Brancati, F., A. Sarkozy, and B. Dallapiccola. 2006. KBG syndrome. OJRD (Orphanet Journal of Rare Diseases). http://www.ojrd.com/content/1/1/50 (accessed August 10, 2010). Braunschweig, F. 2007. Therapeutic and diagnostic role of electrical devices in acute heart failure. Heart Failure Reviews 12(2):157-166. Brodsky, R. A. 2009. How I treat paroxysmal nocturnal hemoglobinuria. Blood 113(26): 6522-6527. Brooks A. D., W. A. Wells, T. D. McLean, R. Khanna, R. Coghlan T. Mertenskoetter, L. A. Privor-Dumm, et al. 2010. Ensuring that developing countries have access to new healthcare products: the role of product development partnerships. Innovation Strategy Today 3:1-5. http://www.ipmglobal.org/pdfs/english/ipm_publications/2010/PDPAccess- InnovationStratToday-Jan2010.pdf (accessed August 23, 2010). Budd, T. M., and K. A. Liebman. 2009. Annual Review of Medical Device Patent Litigation. http://www.faegre.com/showarticle.aspx?Show=9611 (accessed August 10, 2010). Butcher, L. 2009. When should insurers cover off-label drug usage? Managed Care, May. http://www.managedcaremag.com/archives/0905/0905.offlabel.html (accessed August 10, 2010). Campbell, A. 2004. Appendix B: State regulation of medical research with children and ado- lescents: an overview and analysis. In Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press. Pp. 320-383. Campbell, E. G., B. R. Clarridge, M. Gokhale, L. Birenbaum, S. Hilgartner, N. A. Holtzman, and D. Blumenthal. 2002. Data withholding in academic genetics: evidence from a na- tional survey. Journal of the American Medical Association 287(4):473-480. Campbell, G. 2008. Statistics in medical devices and diagnostics. Presentation at the Ad- vaMed-FDA Statistics Workshop, Bethesda, MD. April 16. http://www.amstat.org/ sections/sigmedd/Advamed/Advamed08/presentation/GCampbell_Advamed-FDA_ Statistics_4-08.pdf (accessed August 10, 2010). Campbell, G. 2009. Bayesian statistics at the FDA: The trailblazing experience with medical devices. Presentation at Rutgers Biostatistics Day, New Brunswick, NJ. April 9. http:// www.stat.rutgers.edu/iob/bioconf09/slides/Campbell.pdf (accessed August 9, 2010). Campbell, R. M. 2007. Ensuring safe medicines and medical devices for children. Testimony before the Committee on Health, Education, Labor and Pensions, U.S. Senate, Washing- ton, DC, March 27. http://www.aap.org/advocacy/washing/therapeutics/docs/campbell. pdf (accessed August 27, 2010). Campeau, P. M., C. R. Scriver, and J. J. Mitchell. 2008. A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. Molecular Genetics and Metabolism 95(1-2):11-16. Cannom, D. S., and E. N. Prystowsky. 2004. The evolution of the implantable cardioverter defibrillator. Pacing and Clinical Electrophysiology 27(3):419-421. Carmichael, M. 2010. Would regulation kill genetic testing? Newsweek, June 4. http://www. newsweek.com/2010/06/04/would-regulation-kill-genetic-testing.html (accessed Septem- ber 1, 2010).

OCR for page 249
 REFERENCES Cartier N., S. Hacein-Bey-Abina, C. C. Bartholomae, G. Veres, M. Schmidt, I. Kutschera, M.Vidaud, et al. 2009. Lentiviral-mediated gene therapy of hematopoietic stem cells delays disease progression in patients with a fatal brain disorder. Science 326(5954):818-823. Carver, K. H. C. 2010. Companion diagnostics: evolving FDA regulation and issues for resolu- tion. In In Vitro Diagnostics: The Complete Regulatory Guide, edited by S. D. Danzis and E. J. Flannery. Washington, DC: The Food and Drug Law Institute. Cassidy, A. 2009. Coverage and Payment for Prescription Drugs Under Medicare Part B: A Complex Patchwork. National Health Policy Forum Background Paper. http://www.nhpf. org/library/details.cfm/2755 (accessed August 9, 2010). Cassidy, S. B., and D. J. Driscoll. 2009. Prader-Willi syndrome. European Journal of Human Genetics 17:3-13. Caves, R. E., M. D. Whinston, and M. A. Hurwitz. 1991. Patent expiration, entry, and com- petition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1991:1-48. CBTRUS (Central Brain Tumor Registry of the United States). 2010. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 00-00. http://www.cbtrus.org/2007-2008/2007-20081.html (accessed Au- gust 9, 2010). CDC (Centers for Disease Control and Prevention). 2005. Marine Toxins. http://www.cdc. gov/ncidod/dbmd/diseaseinfo/marinetoxins_g.htm (accessed August 9, 2010). CDC. 2007a. Hemochromatosis for Health Care Professionals: Epidemiology: Prevalence. http://www.cdc.gov/ncbddd/hemochromatosis/training/epidemiology/prevalence.htm (ac - cessed August 9, 2010). CDC. 2007b. Malaria surveillance—United States, 2005. Morbidity and Mortality Weekly Reports 56(SS06):23-38. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5606a2.htm (accessed December 1, 2010). CDC. 2008a. Leishmania Infection. http://www.cdc.gov/ncidod/dpd/parasites/leishmania/ factsht_leishmania.htm#get_us (accessed August 9, 2010). CDC. 2008b. N ocardiosis . http://www.cdc.gov/nczved/divisions/dfbmd/diseases/nocardiosis/ technical.html (accessed August 9, 2010). CDC. 2008c. Schistosomiasis. http://www.cdc.gov/ncidod/dpd/parasites/schistosomiasis/ factsht_schistosomiasis.htm (accessed August 9, 2010). CDC. 2009a. Dengue Epidemiology. http://www.cdc.gov/dengue/epidemiology/index.html (accessed August 9, 2010). CDC. 2009b. Fiscal Year 00: Justification of Estimates for Appropriation Committees. http://www.cdc.gov/fmo/PDFs/FY09_CDC_CJ_Final.pdf (accessed August 9, 2010). CDC. 2009c. HIV/AIDS Surveillance Report: Cases of HIV Infection and AIDS in the United States and Dependent Areas, 00. http://www.cdc.gov/hiv/topics/surveillance/basic. htm#hivest (accessed August 9, 2010). CDC. 2009d. Newborn Screening Translation Research Initiative. http://www.cdcfoundation. org/programs/lifestyles/index.aspx#newborn (accessed August 9, 2010). CDER (Center for Drug Evaluation and Research, Food and Drug Administration). 1998. The CDER Handbook. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ UCM198415.pdf (accessed August 9, 2010). CDER. 2002. Guidance for Industry: Carcinogenicity Study Protocol Submissions. http:// www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm078924.pdf (accessed August 9, 2010). CDER. 2003. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (accessed August 24, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS CDER. 2006. Guidance for Industry, Investigators, and Reviewers: Exploratory IND Stud- ies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm078933.pdf (accessed August 9, 2010). CDER. 2007. Guidance for Industry: Chronic Obstructive Pulmonary Disease: Develop- ing Drugs for Treatment. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm071575.pdf (accessed August 9, 2010). CDER. 2009. CDER Medical Policy Coordinating Committee. Manual of Policies and Pro- cedures November 2. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ ManualofPoliciesProcedures/UCM188694.pdf (accessed August 20, 2010). CDER-CBER (Center for Biologics Evaluation and Research). 1996. Guidance for Industry: E Good Clinical Practice: Consolidated Guidance. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf (accessed August 24, 2010). CDER-CBER. 1997. Guidance for Industry: S Preclinical Evaluation of Biotechnology- Derived Pharmaceuticals. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm074957.pdf (accessed August 24, 2010). CDER-CBER. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf (accessed Au- gust 24, 2010). CDER-CBER. 2002a. Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm126838.pdf (accessed August 24, 2010). CDER-CBER. 2002b. Guidance for Industry: Special Protocol Assistance. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571. pdf (accessed August 24, 2010). CDER-CBER. 2009. Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifi- cations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma tion/Guidances/UCM184128.pdf (accessed August 24, 2010). CDER-CBER. 2010a. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Draft). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM201790.pdf (accessed August 24, 2010). CDER-CBER. 2010b. Guidance for Industry: Non-Inferiority Clinical Trials. http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM202140.pdf (accessed August 24, 2010). CDMRP (Congressionally Directed Medical Research Programs, Department of Defense). 2008. FY 00 Annual Report: Contents. http://cdmrp.army.mil/pubs/annreports/2008 annrep/default.shtml (accessed August 24, 2010). CDRH (Center for Devices and Radiological Health, Food and Drug Administration). 2009. Humanitarian Use Device: Overview. http://www.fda.gov/MedicalDevices/Device RegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/Humanitari anDeviceExemption/default.htm (accessed August 9, 2010). CDRH. 2010a. CDRH Preliminary Internal Evaluations—Volume . August. http://www. fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf (accessed September 3, 2010). CDRH. 2010b. Office of Device Evaluation. http://www.fda.gov/AboutFDA/CentersOffices/ CDRH/CDRHOffices/ucm115879.htm#3 (accessed August 9, 2010).

OCR for page 249
 REFERENCES CDRH-CBER. 2007. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff: In Vitro Diagnostic Multivariate Index Assays. http://www.fda.gov/downloads/Medical Devices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.pdf (accessed August 24, 2010). CDRH-CBER. 2010. Guidance for HDE Holders, Institutional Review Boards (IRBs), Clini- cal Investigators, and FDA Staff—Humanitarian Device Exemption (HDE) Regula- tion: Questions and Answers. http://www.fda.gov/MedicalDevices/DeviceRegulationand Guidance/GuidanceDocuments/ucm110194.htm (accessed August 24, 2010). CDRH-OSB (Office of Surveillance and Biometrics). 2010. Guidance for the Use of Bayes- ian Statistics in Medical Device Clinical Trials. http://www.fda.gov/downloads/Medical Devices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf (accessed August 24, 2010). Celgene. 2010. Thalomid®: System for Thalomide Education and Prescribing Safety. http:// www.thalomid.com/steps_program.aspx (accessed August 9, 2010). CFF (Cystic Fibrosis Foundation). 2008. Research Milestones. http://www.cff.org/research/ ResearchMilestones/ (accessed August 9, 2010). CFF. 2009. Cystic Fibrosis Foundation Patient Registry 00 Annual Data Report. http:// www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf (accessed August 9, 2010). CFF. Undated a. CF Basic Research Centers. http://www.cff.org/aboutCFFoundation/Locations/ ResearchCenters/ (accessed August 9, 2010). CFF. Undated b. CF Foundation-Accredited Care Centers. http://www.cff.org/treatments/Care CenterNetwork/CFFoundation-accreditedCareCenters/ (accessed August 9, 2010). CFSAN (Center for Food Safety and Nutrition), Food and Drug Administration. 2007. Guid- ance for Industry: Frequently Asked Questions About Medical Foods. College Park, MD: FDA. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/Guidance Documents/MedicalFoods/UCM054048#q1 (accessed August 9, 2010). Chamberlain, J. R., U. Schwarze, P. Wang, R. K. Hirata, K. D. Hankenson, J. M. Pace, R. A. Underwood, et al. 2004. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303:1198. http://www.sciencemag.org/cgi/reprint/303/5661/1198.pdf (accessed August 23, 2010). Chan, K., and J. M. Puck. 2005. Development of population-based newborn screening for severe combined immunodeficiency. Journal of Allergy and Clinical Immunology 115:391-398. Chong, C. R., and D. J. Sullivan, Jr. 2007. New uses for old drugs. Nature 448:645-646. August 8. Choudhry, N. K., J. L. Lee, J. Agnew-Blais, C. Corcoran, and W. H. Shrank. 2009. Drug company-sponsored patient assistance programs: A Viable Safety Net? Health Affairs 28(3):827-834. Citron, P. 2008. Medical device considerations. Presentation to IOM Committee on Conflict of Interest in Medical Research, Education, and Practice, Washington, DC. January 21. Clinton, C., and H. T. Gazda. 2009. Diamond-Blackfan Anemia. http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book=gene&part=diamond-b (accessed August 9, 2010). Clyde, A. T., L. Bockstedt, J. A. Farkas, and C. Jackson. 2008. Experience with Medicare’s new technology add-on payment program. Health Affairs 27(6):1632-1641. CMS (Centers for Medicare and Medicaid Services). 2000. Clinical Trials. http://www.cms. gov/manuals/downloads/Pub06_PART_35.pdf (accessed August 9, 2010). CMS. 2006. Guidance for the Public, Industry, and CMS Staff—National Coverage Deter- minations with Data Collection as a Condition of Coverage: Coverage with Evidence Development. July. https://www.cms.gov/mcd/ncpc_view_document.asp?id=8 (accessed August 9, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS CMS. 2007. CMS Manual System. http://www.cms.gov/Transmittals/Downloads/R74NCD. pdf (accessed August 9, 2010). CMS. 2009a. 00 Combined Call Letter. Prescription Drug Coverage Contracting. March 0. http://www.cms.gov/PrescriptionDrugCovContra/Downloads/2010CallLetter.pdf (ac- cessed August 19, 2010). CMS. 2009b. Medicaid Drug Rebate Program: Overview. http://www.cms.gov/Medicaid DrugRebateProgram/ (accessed August 9, 2010). CMS. 2009c. Medicare program; proposed changes to the hospital inpatient prospective pay- ment systems for acute care hospitals and fiscal year 2010 rates and to the long-term care hospital prospective payment system and rate year 2010 Rates; proposed rule. Federal Register 74(98):24080-24686. http://edocket.access.gpo.gov/2009/pdf/E9-10458.pdf (ac- cessed August 9, 2010). CMS. 2009d. Medicare Enrollment: National Trends -00. http://www.cms.gov/ MedicareEnRpts/Downloads/HISMI08.pdf (accessed August 9, 2010). CMS. 2010. Medicare & You 00. http://www.medicare.gov/publications/pubs/pdf/10050. pdf (accessed August 9, 2010). Cohen, W. M., and J. P. Walsh. 2008. Real impediments to biomedical research. In Innova- tion Policy and the Economy, edited by A. B. Jaffe, J. Lerner, and S. Stern. Chicago, IL: University of Chicago Press. Pp. 1-30. Cohn, R. D., C. van Erp, J. P. Habasi, A. A. Soleimani, E. C. Klein, M. T. Lisi, M. Gamradt, et al. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nature Medicine 13:204-210. E-pub January 21. Collins, F. S. 2009. Implementing personalized medicine: scientific and translational challenges. Presentation to AAAS Personalized Medicine: Planning for the Future Colloquium, Washington, DC. October 26. http://www.aaas.org/spp/PM/ppts/Collins.pdf (accessed August 9, 2010). Collins, K. L. 2004. Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health. Perspectives in Biology and Medicine. 47(1):100-109. Cook-Deegan, R. 2008. Gene patents. In From Birth to Death and Bench to Clinic: The Hast- ings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns, edited by Mary Crowley. Garrison, NY: The Hastings Center. Pp. 69-72. http://www.thehast ingscenter.org/uploadedFiles/Publications/Briefing_Book/gene%20patents%20chapter. pdf (accessed August 9, 2010). Coombs, A. 2009. Rare nature of mushroom poisoning means drug trials rarer still. Nature Medicine 15(3). Cornetta, K., and B. Carter. 2010. Letter on Behalf of the American Society of Gene & Cell Therapy to Francis Collins, Director, NIH. March 0. http://www.asgct.org/UserFiles/file/ Francis%20Collins%20Letter.pdf (accessed September 24, 2010). Corr, P. 2008. New business models addressing global health: a framework for private equity. Presentation at IOM Forum on Drug Discovery, Development, and Translation Work- shop on Breakthrough Business Models, Washington, DC. June 23. Cortazar, P. 2007. Clinical review for NDA 22042 [Evista / Raloxifene Hydrochloride]. CDER Medical Review Part  Application Number: 0. September 6. p. 16. http://www. accessdata.fda.gov/drugsatfda_docs/nda/2007/022042s000_MedR_P1.pdf (accessed Au- gust 19, 2010). Coté, T. 2009. The state of the Orphan Drug Act. Presentation to IOM Committee on Ac- celerating Rare Diseases Research and Orphan Product Development, Washington, DC. August 12.

OCR for page 249
 REFERENCES Coté, T. 2010. Orphans at FDA: the fundamentals. Presentation at the American Course on Drug Development and Regulatory Sciences, San Francisco, CA. February 23. C-Path (Critical Path Institute). 2008. FDA and EMEA Conclude That New Renal Safety Biomarkers Are Qualified for Specific Regulatory Purposes. http://www.c-path.org/pdf/ PSTC_nephro_VXDS_summary_final.pdf (accessed August 9, 2010). C-Path. 2009a. Coalition Against Major Disease: Workscope .. http://www.c-path.org/pdf/ CAMDWorkScope.pdf (accessed August 9, 2010). C-Path. 2009b. The Predictive Safety Testing Consortium. http://www.c-path.org/pdf/PSTC_ GeneralInfo_08-28-09.pdf (accessed August 9, 2010). CPI (Critical Path Initiative). 2010. The Critical Path Initiative: Report on Key Achievements in 00. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPath Initiative/UCM221651.pdf (accessed September 24, 2010). CTF (Children’s Tumor Foundation). 2009. 00 Annual Report. http://www.ctf.org/images/ stories/2008_annual_report_final.pdf (accessed August 9, 2010). CTSA (Clinical and Translational Science Awards, NIH). 2010. Evaluation—IRB Issues in Eval- uation. http://www.ctsaweb.org/index.cfm?fuseaction=committee.viewCommittee&com_ ID=461&abbr= (accessed August 10, 2010). CTXinfo.org (Cerebrotendinous xanthomatosis). 2010. Latest News: February . http:// www.ctxinfo.org/index.html (accessed August 9, 2010). Dale, D. C., and D. C. Link. 2009. The many causes of severe congenital neutropenia. New England Journal of Medicine 360(1):3-5. D’Andrea, A. D. 2010. Susceptibility pathways in Fanconi’s anemia and breast cancer. New England Journal of Medicine 362:1909-1919. Defazio, G., G. Abbruzzese, P. Livrea, and A. Berardelli. 2004. Epidemiology of primary dystonia. Lancet Neurology 3(11):673-678. Delude, C. 2009. Tangier disease: one island’s treasure. Proto Magazine Fall:16-21. http:// protomag.com/statics/tangiers.pdf (accessed August 9, 2010). Derbis, J., B. Evelyn, and J. McMeekin. 2008. FDA initiative aims to remove unapproved drugs from market. Pharmacy Today August:21-22. de Siqueira, I. C., J. Dias, H. Ruf, E. A. G. Ramos, E. A. Pires Maciel, A. Rolim, L. Jabur, et al. 2005. Chromobacterium violaceum in siblings, Brazil. Emerging Infectious Diseases (11)9. http://www.cdc.gov/ncidod/EId/vol11no09/pdfs/05-0278.pdf (accessed August 9, 2010). Dhruva, S. S., L. A. Bero, and R. F. Redberg. 2009. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. Journal of the American Medical Association 302(24):2679-2685. Dietz, H. C. 2009. Marfan Syndrome. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= gene&part=marfan (accessed August 9, 2010). Dietz, H. C. 2010. New therapeutic approaches for Mendelian disorders. New England Journal of Medicine 363:852-863. http://www.nejm.org/doi/full/10.1056/NEJMra0907180? query=TOC (accessed September 1, 2010). DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. The price of innovation: new esti- mates of drug development costs. Journal of Health Economics 22(2003):151-185. DiMasi, J. A., L. Feldman, A. Seckler, and A.Wilson. 2010. Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 87:272-277. Dimond, P. F. 2009. Big PhRMA adopting orphan drug strategy. Genetic Engineering & Biotechnology News. http://www.genengnews.com/analysis-and-insight/big-pharma- adopting-orphan-drug-strategy/71053206/ (accessed August 9, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS DNDi (Drugs for Neglected Diseases Initiative). 2009. Pfizer and DNDi Advancing Interna- tional Research Efforts in the Fight Against Neglected Tropical Diseases (press release). http://www.dndi.org/press-releases/2009/565-pfizer-and-dndi-advancing-international- research-efforts-in-the-fight-against-neglected-tropical-diseases.html (accessed August 9, 2010). DOJ (Department of Justice). 2009. Stryker Biotech and Its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries (press release), Oc- tober 28. http://www.fda.gov/downloads/NewsEvents/Newsroom/PressAnnouncements/ UCM188306.pdf (accessed August 24, 2010). Dorman, D. 2007. Testimony submitted by the National Organization for Rare Disorders before the Social Security Administration Public Hearing on Compassionate Allowances, Washington, DC. December 4. Dorman, D. 2008. Statement of Diane Dorman, Vice President for Public Policy National Organization for Rare Disorders (NORD), to FDA Infectious Diseases Planning Com- mittee, Washington, DC. April . http://www.rarediseases.org/pdf/FDA_Infectious_ Diseases_Planning_Com_4-22-08.pdf (accessed August 9, 2010). Dorsey, E. R., J. de Roulet, J. P. Thompson, J. I. Reminick, A. Thai, Z. White-Stellato, C. A. Beck, et al. 2010. Funding of US biomedical research, 2003-2008. Journal of the Ameri- can Medical Association 303(2):137-143. Douglas, J. 2010. Update: Shire plans to undercut Cerezyme as profit rises. Dow Jones News- wires, February 19. http://www.nasdaq.com/aspx/companynewsStoryPrint.aspx?storyid =201002190850dowjonesdjonline000444 (accessed August 9, 2010). Doulton, D. M. 2010. From cradle to commencement: transitioning pediatric sickle cell disease patients to adult providers. Journal of Pediatric Oncology Nursing 27(2):119-123. Dreifus, C. 2009. Researcher behind the drug Gleevec: a conversation with Brian Druker. New York Times, November 2. http://www.nytimes.com/2009/11/03/science/03conv.html (accessed August 9, 2010). Dudley J. T., R. Tibshirani, T. Deshpande, and A. J. Butte. 2009. Disease signatures are robust across tissues and experiments. Molecular Systems Biology 5:307. http://www.ncbi.nlm. nih.gov/pmc/articles/PMC2758720/pdf/msb200966.pdf (accessed August 9, 2010). Duffner, P. K., V. S. Caviness, R. W. Erbe, M. C. Patterson, K. R. Schultz, D. A. Wenger, and C. Whitley. 2009. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genetics in Medicine 11(6):450-454. Duggan, M. 2010. The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review 100(1):590-600. Duggan, M., and F. M. S. Morton. 2006. The distortionary effects of government procure- ment: evidence from Medicaid prescription drug purchasing. Quarterly Journal of Eco- nomics 121(1):1-30. Duncan, D. E. 2009. Enlisting computers to unravel the true complexity of disease. New York Times, August 24. http://www.nytimes.com/2009/08/25/science/25prof.html (accessed August 9, 2010). Duncan, M. W., and S. W. Hunsucker. 2005. Proteomics as a tool for clinically relevant biomarker discovery and validation. Experimental Biology and Medicine 230(11):808-817. Dykxhoorn, D. M., and J. Lieberman. 2006. Knocking down disease with siRNAs. Cell 126(2):231-235. Eastman, P. 2005. Reimbursement policies discourage off-label drug use. Oncology Times 27(20):8, 10. El-Khatib, F. H., S. J. Russell, D. M. Nathan, R. G. Sutherlin, and E. R. Damiano. 2010. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Science Translational Medicine 2(27):27ra27.

OCR for page 249
 REFERENCES Elsas, L. J. 2007. Galactosemia. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene& part=galactosemia (accessed August 9, 2010). EMEA (European Medicines Agency). 2008. Annual Report, 00. London. http://www. ema.europa.eu/docs/en_GB/document_library/Annual_report/2009/12/WC500016591. pdf (accessed December 1, 2010). Entrepreneur Newsletter. 2006. NMT medical voluntarily withdraws Cardioseal PFO HDE (Biotech Equipment Update, October 1). http://www.entrepreneur.com/tradejournals/ article/151492685.html (accessed August 9, 2010). EPI (Economic Policy Institute). 2009. Employer-Sponsored Health Insurance Erosion Contin- ues: Unabated Declines in Coverage Since 000 Are Expected to Worsen Through 00. http://epi.3cdn.net/6356d48ae59f625af6_xxm6bnyn2.pdf (accessed August 9, 2010). Escolar, M. L., M. D. Poe, H. R. Martin, and J. Kurtzberg. 2006. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics 118(3):e879-e889. Eurodis. 2005. Rare diseases in numbers. European Conference on Rare Diseases, Luxem- bourg, June 21-22. http://ec.europa.eu/health/ph_threats/non_com/ev_20050622_co01_ en.pdf (accessed August 6, 2010). European Commission, Health & Consumer Protection Directorate-General. 2007. Public Consultation, Rare Diseases: Europe’s Challenges. http://ec.europa.eu/health/ph_threats/ non_com/docs/raredis_comm_draft.pdf (accessed August 6, 2010). European Union. 1999. Regulation (EC) No. /000. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF (accessed August 6, 2010). Eurostat. 2010. Total Population. http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table& language=en&pcode=tps00001&tableSelection=1&footnotes=yes&labeling=labels& plugin=1 (accessed August 6, 2010). Faik, I., E. de Carvalho, and J. Kun. 2009. Parasite-host interaction in malaria: genetic clues and copy number variation. Genome Medicine 1(9):82. Fanelli, D. 2010. Do pressures to publish increase scientists’ bias? An empirical support from US states data. PLoS ONE 5(4): e10271. http://www.plosone.org/article/info%3Adoi% 2F10.1371%2Fjournal.pone.0010271;jsessionid=EB8BEAAC2BD41631E15776993436 B1B4.ambra01 (accessed August 3, 2010). Farag-El-Massah, S., M. M. Braun, J. Cloyd, S. Schondelmeyer, K. Xu, M. Thomas, D. Lewis, and T. R. Coté. 2009. Quantitative description of FDA designated and approved orphan drugs and biologics. Poster presentation at annual meeting of the Drug Information As- sociation, San Diego, CA. June 22. Farmer, J. 2009. Accelerating rare diseases research and orphan product development: a FARA [Friedreich’s Ataxia Research Alliance] perspective. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23. Farrell, E., and J. Usuka. 2008. Pharmacogenomics and drug development: the impact of U.S. FDA postapproval tracking on clinical pharmacology. Personalized Medicine 5(2):133-139. Faurisson, F. 2004. EurordisCare: Survey of Diagnostic Delays,  Diseases, Europe. http:// archive.eurordis.org/imprimer.php3?id_article=454 (accessed August 6 2010). FDA (Food and Drug Administration). 1996. Guideline for Industry: The Need for Long- Term Rodent Carcinogenicity Studies of Pharmaceuticals. http://www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074911.pdf (accessed August 6, 2010). FDA. 2004. Challenge and Opportunity on the Critical Path to New Medical Products. http:// www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/Critical PathOpportunitiesReports/ucm113411.pdf (accessed September 24, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS NDRI (National Disease Research Interchange). 2003. The Genetics of Rare Disease: Window to Common Disorders (conference). Washington, DC. March 23. NDRI. 2010. NDRI Initiatives: Rare Diseases. http://www.ndriresource.org/NDRI_Initiatives/ Rare_Disease/30/ (accessed August 4, 2010). Neschadim, A., J. A. McCart, A. Keating, and J. A. Medin. 2007. A roadmap to safe, efficient, and stable lentivirus-medicated gene therapy with hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 13(12):1407-1416. Newhouse, J. P., and the Insurance Experiment Group. 1993. Free for All? Lessons from the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press. Ng, S. B., K. J. Buckingham, C. Lee, A. W. Bigham, H. K. Tabor, K. M. Dent, C. D. Huff, et al. 2009. Exome sequencing identifies the cause of a Mendelian disorder. Nature Genet- ics 42(1):30-35. NHGRI (National Human Genome Research Institute). 2009. Learning About Gaucher Dis- ease. http://www.genome.gov/25521505 (accessed August 4, 2010). NHLBI (National Heart, Lung, and Blood Institute). 2000. Expert Panel Review of the NHLBI Total Artificial Heart (TAH) Program June -November . http://www. nhlbi.nih.gov/resources/docs/tahrpt.pdf (accessed August 4, 2010). NHLBI. 2008a. NHLBI Working Group Report: Computational Models for Analyzing Genotype-Phenotype Associations in Rare Diseases. http://www.nhlbi.nih.gov/meetings/ workshops/gpa_rarediseases.htm (accessed August 4, 2010). NHLBI. 2008b. What Is LAM? http://www.nhlbi.nih.gov/health/dci/Diseases/lam/lam_all.html (accessed August 4, 2010). NHLBI. 2009. What Is Aplastic Anemia? http://www.nhlbi.nih.gov/health/dci/Diseases/aplastic/ aplastic_whatis.html (accessed August 4, 2010). NHLBI. 2010. Sickle Cell Disease Awareness and Education Strategy Development Workshop Report. http://www.nhlbi.nih.gov/meetings/workshops/Sickle_Cell_Disease_Workshop. pdf (accessed August 20, 2010). NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases). 2010. Poly- myalgia Rheumatica and Giant Cell Arteritis. http://www.niams.nih.gov/Health_Info/ Polymyalgia/default.asp (accessed August 4, 2010). NIBIB (National Institute of Biomedical Imaging and Bioengineering). 2009. About NIBIB: Mission & History. http://www.nibib.nih.gov/About/MissionHistory (accessed August 4, 2010). NICHD (National Institute of Child Health and Human Development). 2009. NIH Newborn Screening Research Program Named in Memory of Hunter Kelly. http://www.nichd.nih. gov/news/releases/101909-Hunter-Kelly.cfm (accessed August 4, 2010). NIH (National Institutes of Health). 2002. Report on Steps to Coordinate Rare Diseases Research Programs. http://rarediseases.info.nih.gov/Wrapper.aspx?src=asp/html/reports/ fy1999/SEP.html (accessed October 11, 2010). NIH. 2003. Final NIH statement on sharing research data. Notice NOT-OD-0-0. Febru- ary . http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html (accessed August 24, 2010). NIH. 2007. NIH Policy Manual: —Public-Private Partnerships. September 25. http:// oma.od.nih.gov/manualchapters/management/1167/ (accessed August 20, 2010). NIH. 2008. Nocardia Infection. http://www.nlm.nih.gov/medlineplus/ency/article/000679.htm (accessed August 4, 2010). NIH. 2009a. NIH Announces Expansion of Rare Diseases Clinical Research Network. http:// www.nih.gov/news/health/oct2009/od-05.htm (accessed August 4, 2010). NIH. 2009b. NIH Announces New Program to Develop Therapeutics for Rare and Neglected Diseases. http://rarediseases.info.nih.gov/files/TRND%20Press%20Release.pdf (accessed August 4, 2010).

OCR for page 249
 REFERENCES NIH. 2010a. The Cancer Genome Atlas Identifies Distinct Subtypes of Deadly Brain Cancer That May Lead to New Treatment Strategies (news release). http://cancergenome.nih. gov/media/glioblastoma4subtypes.asp (accessed August 4, 2010). NIH. 2010b. Advancing Regulatory Science Through Novel Research and Science-Based Technologies (U0). Request for Applications Number: RFA-RM-0-00. http://grants. nih.gov/grants/guide/rfa-files/RFA-RM-10-006.html (accessed August 4, 2010). Nijsten, T., and P. R. Bergstresser. 2010. Patient advocacy groups: let’s stick together. Journal of Investigative Dermatology 130(7):1757-1759. http://www.nature.com/jid/journal/ v130/n7/pdf/jid2010131a.pdf (accessed September 8, 2010). NNSGRC (National Newborn Screening and Genetics Resource Center). 2010. National Newborn Screening Status Report. http://genes-r-us.uthscsa.edu/nbsdisorders.pdf (ac- cessed August 4, 2010). NORD (National Organization for Rare Disorders). 2003. NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins. NORD. 2007. Testimony Before the Social Security Administration Public Hearing on Compas- sionate Allowances. Washington, DC. December . http://www.ssa.gov/compassionateallow ances/NORDTestimonyCompassionateAllowances120407.pdf (accessed August 4, 2010). NORD. 2010. NORD Reports Progress in Appropriations Bill. http://www.rarediseases. org/news/Appropriations_Progress (accessed August 4, 2010). NRC (National Research Council). 2000. Bioinformatics: Converting Data to Knowledge: Workshop Summary. Washington, DC: National Academy Press. NRC. 2006. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Prop- erty Rights, Innovation and Public Health. Washington, DC: The National Academies Press. NRC. 2007. The New Science of Metagenomics: Revealing the Secrets of Our Microbial Planet. Washington, DC: The National Academies Press. NRC. 2009. A New Biology for the st Century: Ensuring the United States Leads the Com- ing Biology Revolution. Washington, DC: The National Academies Press. NTP (National Toxicology Program). 2004. Technical Report on the Toxicology and Carci- nogenesis Studies of Elmiron. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr512.pdf (ac- cessed August 13, 2010). Nussbaum, R. L., R. R. McInnes, and H. F. Willard. 2004. Thompson & Thompson Genetics in Medicine, th Edition. Philadelphia, PA: W.B. Saunders Company. Nutt, B. 2007. From the Other Side of the Stethoscope. http://www.thelamfoundation.org/ patients/living-with-lam/patient-storiesAll.html/#Nutt (accessed August 4, 2010). Nwaka, S., and R. G. Ridley. 2003. Virtual drug discovery and development for neglected dis- eases through public-private partnerships. Nature Reviews Drug Discovery 2:919-928. Öfverholm, A., E. Arkblad, S. Skrtic, P. Albertsson, E. Shubbar, and C. Enerbäck. 2010. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clinical Biochemistry 43(3):331-334. OHRP (Office of Human Research Protections). 2008. OHRP Research Involving Children Frequently Asked Questions. http://www.hhs.gov/ohrp/researchfaq.html (accessed Au- gust 4, 2010). OIG (Office of the Inspector General, DHHS). 2001a. Medicare Hospital Prospective Payment System: How DRG Rates Are Calculated and Updated. http://oig.hhs.gov/oei/reports/ oei-09-00-00200.pdf (accessed August 4, 2010). OIG. 2001b. The Orphan Drug Act Implementation and Impact. http://oig.hhs.gov/oei/ reports/oei-09-00-00380.pdf (accessed August 4, 2010). OIG. Undated. Rare Diseases and Related Terms. http://rarediseases.info.nih.gov/RareDisease List.aspx (accessed August 4, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS OOPD (Office of Orphan Product Development, FDA). 2009. Recipients of the FY0 Pediatric Device Consortia Grant Program Awards. http://www.fda.gov/ForIndustry/Developing ProductsforRareDiseasesConditions/WhomtoContactaboutOrphanProductDevelopment/ ucm184125.htm (accessed August 4, 2010). OOPD. 2010. New Resource for Drug Developers: The Rare Disease Repurposing Database (RDRD). http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesCondi tions/HowtoapplyforOrphanProductDesignation/ucm216147.htm (accessed September 24, 2010). ORDR (Office of Rare Diseases Research, NIH). 2009. Office of Rare Diseases Research (ORDR) Brochure. http://rarediseases.info.nih.gov/Wrapper.aspx?src=asp/resources/ord_ brochure.html (accessed August 4, 2010). Orphanet. 2009. Prevalence of Rare Diseases. Orphanet Report Series, No. 1, November. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alpha betical_list.pdf (this link is to a more recent version of the report than was used by the committee). Orphanet. Undated a. About Orphanet: Mission. http://www.orpha.net/consor/cgi-bin/ Education_AboutOrphanet.php?lng=EN (accessed August 4, 2010). Orphanet. Undated b. About Rare Diseases. http://www.orpha.net/consor/cgi-bin/Education_ AboutRareDiseases.php?lng=EN (accessed August 4, 2010). Outterson, K., and A. S. Kesselheim. 2009. How Medicare could get better prices on prescrip- tion drugs. Health Affairs 28(5):w832-841. Pannicke, U., M. Honig, I. Hess, C. Friesen, K. Holzmann, E. M. Rump, T. F. Barth, et al. 2009. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nature Genetics 41(1):101-105. Pariser, A. 2010. FDA regulation and review of small clinical trials. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4. Patel, C. J., J. Bhattacharya, and A. J. Butte. 2010. An environment-wide association study (EWAS) on type 2 diabetes mellitus. Public Library of Science ONE 5(5):e10746. Patterson, M. 2008. Niemann-Pick Disease Type C. http://www.ncbi.nlm.nih.gov/bookshelf/ br.fcgi?book=gene&part=npc (accessed August 3, 2010). Pfizer. 2010. Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® (press release). http:// media.pfizer.com/files/news/press_releases/2010/mylotarg_discontinuation_062110.pdf (accessed August 3, 2010). Pharmaceutical Forum, E.C. 2008. Improving access to orphan medicines for all affected EU citizens. Reference Document  in High Level Pharmaceutical Forum 00-00 Final Report. http://ec.europa.eu/pharmaforum/docs/pricing_orphans_en.pdf (accessed August 3, 2010). PhRMA (Pharmaceutical Research and Manufacturers of America). 2007. Drug Discovery and Development: Understanding the R & D Process. Washington, DC. http://www.phrma. org/files/attachments/RD%20Brochure%20022307.pdf (accessed August 27, 2010). Pietzsch, J. B., L. A. Shluzas, M. E. Paté-Cornell, P. G. Yock, and J. H. Linehan. 2009. Stage- gate process for the development of medical devices. Journal of Medical Devices 3(2). Pion, G., and M. Ionescu-Pioggia. 2003. Bridging postdoctoral training and a faculty position: initial outcomes of the Burroughs Wellcome Fund Career Awards in the Biomedical Sci- ences. Academic Medicine 78(2):177-186.

OCR for page 249
 REFERENCES PMC (Personalized Medicine Coalition). 2009. Comments on Development of Companion Di- agnostics and the April 00 Food and Drug Administration (“FDA”) Drug-Diagnostic Co-development Concept Paper. December . http://www.personalizedmedicinecoalition. org/sites/default/files/files/FDA%20CoDevelopment%20FINAL%20Version%20PDF.pdf (accessed August 4, 2010) Pober, B. R. 2010. Williams-Beuren syndrome. New England Journal of Medicine 362(3): 239-252. Pollack, A. 2008. Cutting dosage of costly drug spurs a debate. New York Times, March 16. Pollack, A. 2009. Pfizer deal signals a move into treating rare diseases. New York Times, December 2. http://query.nytimes.com/gst/fullpage.html?res=9C0DE5D8153BF931A35 751C1A96F9C8B63&sec=&spon=&pagewanted=print (accessed August 3, 2010). Pollack, A. 2010. After gene patent is invalidated, taking stock. New York Times, March 30. http://www.nytimes.com/2010/03/31/business/31gene.html (accessed August 20, 2010). PRF (Progeria Research Foundation). 2008. The Progeria Research Foundation Timeline. http://progeriaresearch.org/assets/files/pdf/Timeline%20Nov%2007.pdf (accessed August 3, 2010). Prosser, L. A., C. Y. Kong, D. Rusinak, and S. L. Waisbren. 2010. Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 125:e286-e294. Q1Medicare.com. 2009. PDP—Facts: 00 Medicare Part D Plan Statistics—Region (State) and National. http://www.q1medicare.com/PartD-MedicarePartDPlanStatisticsState.php? crit=National (accessed August 3, 2010). Radcliffe, S. 2009. BIO (Biotechnology Industry Organization). Statement to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Development, Washington, DC. November 23. http://www.bio.org/reg/20091123.pdf (accessed August 2, 2010). Radley, D. C., S. N. Finkelstein, and R. S. Stafford. 2006. Off-label prescribing among office- based physicians. Archives of Internal Medicine 166(9):1021-1026. Rai, A. K., J. H. Reichman, P. F. Uhlir, and C. Crossman. 2008. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. Yale Journal of Health Policy, Law, and Ethics VIII(I):52-89. http://scholarship.law.duke.edu/cgi/view content.cgi?article=2329&context=faculty_scholarship (accessed August 3, 2010). Rappaport, B. 2010. Division director summary basis for recommendation of approval ac- tion. Summary Review, Application Number  [Xiaflex]. February 1. http://www. accessdata.fda.gov/drugsatfda_docs/nda/2010/125338s000SumR.pdf (accessed August 3, 2010). Ray, T. 2010. FDA Chief Commits to Completing Rx/Dx Codevelopment Guidance This Year, Improving Regulatory Science. http://www.genomeweb.com/dxpgx/fda-chief-commits- completing-rxdx-codevelopment-guidance-year-improving-regulato (accessed August 3, 2010). RegenceRx. 2010. Off-Label Use of FDA-Approved Drugs. http://blue.regence.com/trgmedpol/ drugs/dru031.pdf (accessed August 3, 2010). Reich, M. R. 2000. The global drug gap. Science 287(5460):1979-1981. Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. Monoclonal antibody successes in the clinic. Nature Biotechnology 23:1073-1078. Reiffen, D., and M. R. Ward. 2005. Generic drug industry dynamics. Review of Economics and Statistics 87(1):37-49. Richey, E. A., E. A. Lyons, J. R. Nebeker, V. Shankaran, J. M. McKoy, T. H. Luu, N. Nonzee, et al. 2009. Accelerated approval of cancer drugs: improved access to therapeutic break- throughs or early release of unsafe and ineffective drugs? Journal of Clinical Oncology 27(26):4398-4405. Ridley, D. 2009. Business of Drug Discovery. http://gspp.berkeley.edu/iths/RDStrategies/ lecture4.ppt#425,1,Business of Drug Discovery (accessed August 3, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS Ridley, R. G. 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415(6872):686-693. Ridley, R. G. 2003. Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships. EMBO Reports. Spec No: S43-46. http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC1326445/pdf/4-embor858.pdf (accessed August 3, 2010). Rinaldi, A. 2005. Adopting an orphan. EMBO Reports 6(6):507-510. Riordan J. R., J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066-1073. Roach, J. C., G. Glusman, A. F. Smit, C. D. Huff, R. Hubley, P. T. Shannon, L. Rowen, et al. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequenc- ing. Science. http://www.sciencemag.org/cgi/rapidpdf/science.1186802v1.pdf (accessed August 3, 2010). Roca, R. 2009. Summary review for regulatory action. Summary Review, Application Number - [Colcrys / colchicine]. July 30. http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2009/022352s000_SumR.pdf (accessed August 19, 2010). Rockoff, R. D. 2010. An old gout drug gets new life and a new price, riling patients. Wall Street Journal, April 12. http://online.wsj.com/article/NA_WSJ_PUB:SB1000142405274 8703630404575053303739829726.html (accessed August 27, 2010). Rosebraugh, C. 2010. Approval Letter to Auxilium Pharmaceuticals, Inc. for BLA 125338/0 [Xiaflex]. February 2. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/ 125338s000ltr.pdf (accessed August 20, 2010). Rosecrans, H. 2010. Understanding the premarket notification (510(k)) process. Presentation at Public Health Effectiveness of the FDA 510(k) Clearance Process, Washington, DC. February 18. Rosenberg, H., M. Davis, D. James, N. Pollock, and K. Stowell. 2007. Malignant hyperther- mia. Orphanet Journal of Rare Diseases 2(1):21. Rosenstein, B. J., and G. R. Cutting. 1998. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 132(4):589-595. Rubinstein, Y. R., S. C. Groft, R. Barteck, K. Brown, R. A. Christensen, E. Collier, A. Farber, et al. 2010. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemporary Clinical Trials 31(5):394-404. SACGHS (Secretary’s Advisory Committee on Genetics, Health, and Society). 2008. U.S. System of Oversight of Genetic Testing. http://oba.od.nih.gov/oba/SACGHS/reports/ SACGHS_oversight_report.pdf (accessed August 3, 2010). Sands, S. 2010. IFib. Living with DMD. May . http://dmdpioneers.org/home/living-with- dmd/ifib (accessed August 20, 2010). Sardiello, M. P., A. di Ronza, D. L. Medina, M. Valenza, V. A. Gennarino, C. D. Malta, F. Donaudy, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science 325(5939):473-477. Sasinowski, F. 2010. Statement of the National Organization for Rare Disorders (NORD) at the U.S. Food and Drug Administration Part 15 Public Hearing: Considerations Regard- ing FDA Review and Regulation of Articles for the Treatment of Rare Disease. Silver Spring, MD, June 29. http://www.rarediseases.org/files/NORD-statement-FDA-hearing- 06-29-10.pdf (accessed August 3, 2010). Sauer M., S. Grewal, and C. Peters. 2004. Hematopoietic stem cell transplantation for muco- polysaccharidoses and leukodystrophies. Klinische Pädiatrie 216:163-168. Sawyers, C. L. 2010. Even better kinase inhibitors for chronic myeloid leukemia. New England Journal of Medicine 362:2314-2315.

OCR for page 249
 REFERENCES Schact, W. H. 2007. The Bayh-Dole Act: Selected Issues in Patent Policy and the Commercial- ization of Technology. Congressional Research Service Report RL32076. http://fpc.state. gov/documents/organization/96463.pdf (accessed September 2, 2010). Schact, W. H., and J. R. Thomas. 2009. Follow-on Biologics: Intellectual Property and In- novation Issues. Congressional Research Service Report RL33901. http://assets.opencrs. com/rpts/RL33901_20090803.pdf (accessed August 3, 2010). Schadt, E. E., A. Sachs, and S. Friend. 2005a. Embracing complexity, inching closer to reality. Science Signaling 295:pe40. 295:pe40. Schadt, E. E., J. Lamb, X. Yang, J. Zhu, S. Edwards, D. Guhathakurta, S. K. Sieberts, et al. 2005b. An integrative genomics approach to infer causal associations between gene expression and disease. Nature Genetics 37(7):710-717. Scheinberg, I. H., and J. M. Walshe. 1986. Orphan Diseases and Orphan Drugs. Manchester, UK: Manchester University Press. Schickedanz, A. D., and R. D. Herdman. 2009. Direct-to-consumer genetic testing: the need to get retail genomics right. Clinical Pharmacology and Therapeutics 86(1):17-20. Schimke, R. N., D. L. Collins, and C. A. Stolle. 2009. Von Hippel-Lindau Syndrome. http:// www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=vhl#vhl.grID1694 (accessed August 3, 2010). Schmitz, J., L. W. Poll, and S. vom Dahl. 2007. Therapy of adult Gaucher disease. Haemato- logica 92(2):148-152. Schofield, P. N., T. Bubela, T. Weaver, L. Portilla, S. D. Brown, J. M. Hancock, D. Einhorn, et al. 2009. Post-publication sharing of data and tools. Nature 461:171-173. Schulte, F., and D. Donovan. 2007. Drug earning millions despite “orphan” label: Status granted before law increased use of “bupe.” Baltimore Sun. Schultz, D. 2008. FDA public health notification: life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. FDA, Alerts and Notices (Medical Devices). July 1. http://www.fda.gov/MedicalDevices/Safety/ AlertsandNotices/PublicHealthNotifications/UCM062000 (accessed August 12, 2010). Scriver, C. R., and P. J. Lee. 2004. The last day of the past is the first day of the future: tran- sitional care for genetic patients. American Journal of Medicine 117(8):615-617. Scriver, C. R., and E. P. Treacy. 1999. Is there treatment for “genetic” disease? Molecular Genetics and Metabolism 68(2):93-102. Segal, J. B., J. J. Strouse, M. C. Beach, C. Haywood, C. Witkop, H. Park, R. F. Wilson, et al. 2008. Evidence Report/Technology Assessment: Hydroxyurea for the Treatment of Sickle Cell Disease. AHRQ Publication No. 08-E007. http://www.ahrq.gov/downloads/pub/ evidence/pdf/hydroxyurea/hydroxscd.pdf (accessed August 3, 2010). Seoane-Vazquez, E., R. Rodriguez-Monguio, S. L. Szeinbach, and J. Visaria. 2008. Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases 3(33). http://www.ojrd.com/content/pdf/1750-1172-3-33.pdf (accessed August 3, 2010). Shah, R. R. 2006. Regulatory framework for the treatment of orphan diseases. In Fabry Disease: Perspectives from  Years of FOS, edited by A. Mehta, M. Beck, and G. Sunder- Plassmann. Oxford, UK: Oxford PharmaGenesis. http://www.ncbi.nlm.nih.gov/book shelf/br.fcgi?book=fabry&part=A745 (accessed August 3, 2010). Sing, C. F., J. H. Stengard, and S. L. R. Kardia. 2003. Genes, environment, and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 23(7):1190-1196. Smith, V. K., K. Gifford, E. Ellis, R. Rudowitz, M. O. M. Watts, and C. Marks. 2009. The Crunch Continues: Medicaid Spending, Coverage and Policy in the Midst of a Recession. http://www.kff.org/medicaid/upload/7985.pdf (accessed August 3, 2010).

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS Smits, P., A. D. Bolton, V. Funari, M. Hong, E. D. Boyden, L. Lu, D. K. Manning, et al. 2010. Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210. New Eng- land Journal of Medicine 362(3):206-216. So, A. D., and E. Stewart. 2009. Appendix F: Sharing knowledge for global health. In The U.S. Commitment to Global Health: Recommendations for the Public and Private Sectors. Institute of Medicine. Washington, DC: The National Academies Press. http://www.ncbi. nlm.nih.gov/bookshelf/br.fcgi?book=nap12642&part=a2001902dddd00191#a2001902d nnn00053 (accessed August 24, 2010). Solomon, M. D., D. P. Goldman, G. F. Joyce, and J. J. Escarce. 2009. Cost sharing and the initiation of drug therapy for the chronically ill. Archives of Internal Medicine 169(8):740-748. Sotos, J. G. 1989. Zebra Cards: An Aid to Obscure Diagnoses. Philadelphia, PA: American College of Physicians. Sox, H. C. 2009. Evaluating off-label uses of anticancer drugs: time for a change. Annals of Internal Medicine 150(5):353-354. Spiration, Inc. 2009. CMS Approves New Technology Add-on Payment for Spiration® IBV Valve System (press release). August . http://www.spiration.com/downloads/NTAPPress ReleaseFinal.pdf (accessed August 3, 2010). SSA (Social Security Administration). 2010a. Compassionate Allowances. http://www.social security.gov/compassionateallowances/ (accessed August 3, 2010). SSA. 2010b. Medicare. http://www.ssa.gov/pubs/10043.pdf (accessed August 3, 2010). Statistics Bureau (Japan). 2008. Statistical Handbook of Japan: Chapter  Population. http:// www.stat.go.jp/english/data/handbook/c02cont.htm (accessed August 3, 2010). Stein, R. 2010. FDA considers revoking approval of Avastin for advanced breast cancer. Washington Post, August 16. http://www.washingtonpost.com/wp-dyn/content/article/ 2010/08/15/AR2010081503466.html (accessed September 1, 2010). Stein, S., M. G. Ott, S. Schultze-Strasser, A. Jauch, B. Burwinkel, A. Kinner, M. Schmidt, et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 16(2):198-204. E-pub January 24. Steinberg, K. K., M. E. Cogswell, J. C. Chang, S. P. Caudill, G. M. McQuillan, B. A. Bowman, L. M. Grummer-Strawn, et al. 2001. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. Journal of the American Medical As- sociation 285:2216-2222. Steiner, R. 2009. Sitosterolemia. March . http://emedicine.medscape.com/article/948892- overview (accessed August 3, 2010). Steiner R. D., S. L. Huhn, T. Koch, A. Al-Uzri, G. Guillaume, T. Sutcliffe, H. Vogel, and N. Selden. 2009. CNS transplantation of purified human neural stem cells in infantile and late-infantile neuronal ceroid lipofuscinoses: summary of the Phase I trial. Abstracts for the 11th International Congress of Inborn Errors of Metabolism. Molecular Genetics and Metabolism 98(1-2):76 (A422). Stoffels, P. 2009. Collaborative innovation for the post-crisis world. Boston Globe, Febru- ary 2. http://www.boston.com/bostonglobe/editorial_opinion/oped/articles/2009/02/02/ collaborative_innovation_for_the_post_crisis_world?mode=PF (accessed August 3, 2010). Stossel, T. P. 2008. The discovery of statins. Cell 134(6): 903-905. http://download.cell.com/ pdf/PIIS0092867408011276.pdf?intermediate=true (accessed August 11, 2010). Stratman, R. C., J. D. Flynn, and K. W. Hatton. 2009. Malignant hyperthermia: a pharmaco- genetic disorder. Orthopedics 32:835. Straube, B. M. 2009. Update: CMS and genetic applications in health care. Presentation to SACGHS Meeting, Washington, DC. March 12. http://oba.od.nih.gov/oba/SACGHS/ meetings/March2009/Straube_slides.pdf (accessed August 3, 2010).

OCR for page 249
 REFERENCES Sung, N. S., W. F. Crowley, Jr., M. Genel, P. Salber, L. Sandy, L. M. Sherwood, S. B. Johnson, et al. 2003. Central challenges facing the national clinical research enterprise. Journal of the American Medical Association 289(10):1278-1287. Suthram, S., J. T. Dudley, A. P. Chiang, R. Chen, T. J. Hastie, and A. J. Butte. 2010. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Computational Biology 6(2): e1000662. http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal. pcbi.1000662 (accessed August 3, 2010). Suzuki, M., K. Wlers, E. B. Brooks, K. D. Grels, K. Halnes, M. S. Klein-Gittleman, J. Olson, et al. 2009. Initial validation of a novel protein biomarker for active pediatric lupus nephritis. Pediatric Research 65(5):530-536. Swann, J. P. 2003. The history of the FDA. In The Food and Drug Administration, edited by M. A. Hickman. Hauppauge, NY: Nova Science Publishers. Swanson, J. 2009. Companion diagnostics take off. Genome Technology. http://www.genome web.com/dxpgx/companion-diagnostics-take (accessed August 3, 2010). Tabor, H. K., and M. Bamshad. 2010. Exome sequencing and rare diseases. Presentation to IOM Committee on Accelerating Rare Diseases Research and Orphan Product Develop- ment, Washington, DC. February 4. TDR (Special Programme for Research and Training in Tropical Diseases). 2008. BL3—drug discovery on fast track says expert advisors. TDRnews. May. http://apps.who.int/tdr/svc/ publications/tdrnews/issue-80/drug-discovery-fast-track (accessed August 20, 2010). Tejada, P. 2009. Towards an International Standard of Coding and Classification of Rare Diseases. http://archive.eurordis.org/imprimer.php3?id_article=2014 (accessed August 3, 2010). Terry, S. F. 2009. Written statement for Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, U.S. House of Representatives, March 18. http://www.geneticalliance.org/statements.terry (accessed August 3, 2010). Terry, S. F. 2010. Accelerate medical breakthroughs by ending disease earmarks. Nature Re- views Genetics 11:310-311. Thaul, S. 2008. FDA Fast Track and Priority Review Programs. Congressional Research Ser- vice RS22814 (http://nationalaglawcenter.org/assets/crs/RS22814.pdf) (accessed August 27, 2010). Therrell, B., F. Lorey, R. Eaton, D. Frazier, G. Hoffman, C. Boyle, D. Green, et al. 2008. Impact of expanded newborn screening. Morbidity and Mortality Weekly Report 57(37):1012- 1015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5737a2.htm (accessed August 3, 2010). Thomson, G., N. Marthandan, J. A. Hollenbach, S. J. Mack, H. A. Erlich, R. M. Single, M. J. Waller, et al. 2010. Sequence feature variant type (sfvt) analysis of the hla genetic associa- tion in juvenile idiopathic arthritis. Pacific Symposium on Biocomputing 15:359-370. Tillman, D. B. 2010. Approval letter for Medtronic Melody® Transcatheter Pulmonary Valve and Medtronic Ensemble® Transcatheter Valve Delivery System (H080002). January 25. http://www.accessdata.fda.gov/cdrh_docs/pdf8/H080002a.pdf (accessed August 19, 2010). Tillman, D. B., and S. Gardner. 2004. Letter to Institute of Medicine committee on postmarket surveillance of pediatric medical devices, September 27. As cited in Safe Medical Devices for Children. 2006. Washington, DC: The National Academies Press. Tollefson, L. 2008. Letter to Donald M. Poretz, President, Infectious Diseases Society of America Concerning the Orphan Drug Act, October . http://www.hivma.org/ WorkArea/DownloadAsset.aspx?id=16139 (accessed August 24, 2010).

OCR for page 249
0 RARE DISEASES AND ORPHAN PRODUCTS Torreele, E., M. Usdin, and P. Chirac. 2004. A needs-based pharmaceutical R&D agenda for neglected diseases. Paper prepared for the WHO Commission on Intellectual Property Rights, Innovation and Public Health. Version 31. July. http://www.who.int/intellectual property/topics/research/Needs%20based%20R&D%20for%20neglected%20diseases% 20Els%20Pierre%20Martine.pdf (accessed September 7, 2010). Trafton, A. 2010. Revolutionizing medicine one chip at a time. MIT News, March 9. Travis, J. 2008. Science by the masses. Science 319(5871):1750-1752. Trikalinos, T. A., M. Chung, J. Lau, and S. Ip. 2009. Systematic review of screening for bili- rubin encephalopathy in neonates. Pediatrics 124(4):1162-1171. Tse, T., R. J. Williams, and D. A. Zarin. 2009. Reporting “basic results” in ClinicalTrials.gov. Chest 136(1):295-303. Tufts Center for the Study of Drug Development. 2010. U.S. orphan product designations more than doubled from 2000-02 to 2006-08. Impact Report 12(1). Ulatowski, T. 2009. Warning Letter to William Birdsall, Chief Executive Officer, MicroMed Technology, Inc. RE: DeBakey VAD Child. http://www.fda.gov/ICECI/Enforcement Actions/WarningLetters/ucm195995.htm (accessed August 19, 2010). Unger, E. F., A. M. Thompson, M. J. Blank, and R. Temple. 2010. Erythropoiesis-stimulating agents—time for a reevaluation. New England Journal of Medicine 362(3):189-192. UNOS (United Network for Organ Sharing). 2010. Financing a Transplant. http://www. transplantliving.org/beforethetransplant/finance/costs.aspx (accessed August 3, 2010). U.S. Census Bureau. 2001. Monthly Estimates of the United States Population: April , 0 to July , , with Short-Term Projections to November , 000. http://www.census. gov/population/estimates/nation/intfile1-1.txt (accessed August 3, 2010). U.S. Census Bureau. 2009. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April , 000 to July , 00 (NST-EST00-0). Washington, DC. http://www.census.gov/popest/states/tables/NST-EST2009-01.xls (ac- cessed August 3, 2010). U.S. Congress, Senate Committee on Appropriations. 2008. Report on S. 0 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropria- tion Bill. Washington, DC. UTHSCSA (University of Texas Health Science Center San Antonio). 2004. Titanium Rib Becomes st New FDA-Approved Spine Deformity Treatment in 0 Years (press re- lease). http://www.uthscsa.edu/hscnews/singleformat2.asp?newID=1148 (accessed August 3, 2010). Valeo, T. 2010. New molecule found to cross the blood-brain barrier: reported safe for pa- tients with progressive glioma. Neurology Today 10(1):12-13. http://journals.lww.com/ neurotodayonline/Fulltext/2010/01070/New_Molecule_Found_to_Cross_the_Blood_ Brain.8.aspx (accessed August 3, 2010). Van Eyk, J. E. 2010. Development of biomarkers. Presentation to IOM Committee on Ac- celerating Rare Diseases Research and Orphan Product Development, Washington, DC. February 4. VCRC (Vasculitis Clinical Research Consortium). 2010. What Is the VCRC? http://rarediseases network.epi.usf.edu/vcrc/about/index.htm (accessed August 3, 2010). Villa, S., A. Compagni, and M. R. Reich. 2008. Orphan drug legislation: lessons for neglected tropical diseases. International Journal of Health Planning and Management. http://www. wcfia.harvard.edu/sites/default/files/Reich_Orphan.pdf (accessed August 3, 2010). Villarreal, M. A. 2001. Orphan Drug Act: Background and Proposed Legislation in the 0th Congress. Congressional Research Service Report RS20971. http://www.policyarchive. org/handle/10207/bitstreams/3490.pdf (accessed August 3, 2010). Vodovotz, Y., M. Csete, J. Bartels, S. Chang, and G. An. 2008. Translational systems biology of inflammation. Public Library of Science Journal Computational Biology 4(4).

OCR for page 249
 REFERENCES Wade, N. 2010. Disease cause is pinpointed with genome. New York Times. http://www. nytimes.com/2010/03/11/health/research/11gene.html (accessed August 3, 2010). Wagner, J. A., M. Prince, E. C. Wright, M. M. Ennis, J. Kochan, D. J. R. Nunez, B. Schneider, et al. 2010. The biomarkers consortium: practice and pitfalls of open-source precompeti- tive collaboration. Clinical Pharmacology and Therapeutics 87:539-542. Walpoth, B. H., and G. L. Bowlin. 2005. The daunting quest for a small diameter vascular graft. Expert Review of Medical Devices 2(6):647-651. Wang, D., T. Wood, M. Sadilek, C. R. Scott, F. Turecek, and M. H. Gelb. 2007. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clinical Chemistry 53:137-140. Wang, S. S. 2010. Drug makers will share data from failed Alzheimer’s trials. Wall Street Journal, June 11. http://online.wsj.com/article/SB100014240527487036277045752987 83153884208.html (accessed August 3, 2010). Wasserstein, J. N., and K. R. Karst. 2007. Orphan Drug Designation Not Sacrosanct—FDA Revokes Orphan Designation for TheraCLEC for EPI, but Other Exclusivity Issues Remain. July . http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2007/07/fda- revokes-alt.html (accessed August 3, 2010). Watson, M. S., Marie Y. Mann, M. A. Lloyd-Puryear, P. Rinaldo, and R. R. Howell. 2006. Newborn screening: toward a uniform screening panel and system. Genetics in Medicine 8(5). Waxman, H. J. Undated. Orphan Drugs. http://waxman.house.gov/IssueList/Internal/orphan drugs.htm (accessed August 3, 2010) Wechsler, J. 2008. Orphan drug R&D challenges sponsors. Applied Clinical Trials. http:// appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Orphan-Drug- RampD-Challenges-Sponsors/ArticleStandard/Article/detail/527733 (accessed August 3, 2010). Weiss, K. D. 2005. Approval Letter to BioMarin Pharmaceutical, Incorporated for BLA 125117 [Galsulfase / Naglazyme]. May 31. http://www.accessdata.fda.gov/drugsatfda_ docs/appletter/2005/125117_0000_ltr.pdf (accessed August 23, 2010). Wellman-Labadie, O., and Y. Zhou. 2009. The U.S. Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 95(2-3):216-228. Wellmark Blue Cross Blue Shield. 2009. Humanitarian Use Devices: Medical Policy 0.0.. http://www.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/ Policies/Humanitarian_Use_Devices.aspx (accessed August 3, 2010). Wellmark Blue Cross Blue Shield. 2010. Off-label Drug Use (Medical Policy). http://wwwprep. wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/policies/_Off- label_Drug_UsePrinterFriendly.aspx (accessed August 3, 2010). Whalen, J. 2009. Novartis shifts focus to rare diseases. Wall Street Journal, December 21. WHO (World Health Organization). 2009a. Global Tuberculosis Control, Epidemiology. http://www.who.int/tb/publications/global_report/2009/pdf/chapter1.pdf (accessed Au- gust 3, 2010). WHO. 2009b. Leishmaniasis: Burden of Disease. http://www.who.int/leishmaniasis/burden/ en/ (accessed August 3, 2010). Wolf, B. 2008. Biotinidase Deficiency [Late-Onset Biotin-Responsive Multiple Carboxylase Deficiency, Late-Onset Multiple Carboxylase Deficiency]. http://www.ncbi.nlm.nih.gov/ bookshelf/br.fcgi?book=gene&part=biotin (accessed August 3, 2010). Wolfe, J. H. 2009. Gene therapy in large animal models of human genetic diseases. Institute for Laboratory Animal Research Journal 50(2):107-111.

OCR for page 249
 RARE DISEASES AND ORPHAN PRODUCTS Wolfe, L. C. 2010. Chronic granulomatous disease: treatment and medication. eMedicine April 16. http://emedicine.medscape.com/article/956936-treatment (accessed August 11, 2010). Wolff, A. C. 2009. The controversy: perspectives on HER2 testing for breast cancer. ASCO News & Forum. http://www.ascoconnection.org/LinkClick.aspx?fileticket= gN-fxKFh0xA%3d&tabid=78 (accessed August 3, 2010). Wong, H. R., N. Cvijanovich, G. L. Allen, R. Lin, N. Anas, K. Meyer, R. J. Freishtat, et al. 2009. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Critical Care Medicine 37(5):1558-1566. Wong, H. S., and H. Q. Wang. 2008. Constructing the gene regulation-level representation of microarray data for cancer classification. Journal of Biomedical Informatics 41(1):95- 105. E-pub April 11, 2007. Wood, A. J. J. 2006. A proposal for radical changes in the drug-approval process. New En- gland Journal of Medicine 355(6):618-623. Woodward, E. R., and E. R. Maher. 2006. Von Hippel-Lindau disease and endocrine tumor susceptibility. Endocrine-Related Cancer 13(2):415-425. http://www.ncbi.nlm.nih.gov/ pubmed/16728571?dopt=Abstract (accessed August 20, 2010). Woolf, S. H. 2008. The meaning of translational research and why it matters. Journal of the American Medical Association 299(2):211-213. Yaplito-Lee, J., J. Pitt, J. Meijer, L. Zoetekouw, R. Meinsma, and A. B. van Kuilenburg. 2008. beta-Ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. Molecular Genetics and Metabolism 93(2):190-194. Yong, G., M. H. Salinger, and T. E. Feldman. 2007. Device closure for PFO: the data and devices associated with percutaneous PFO closure. Cardiac Interventions Today June:32-40. Zacks, R. 2008. Artificial heart finally ready for market? Abiomed’s potential “billion-dollar monopoly.” xconomy, January 23. http://www.xconomy.com/2008/01/23/artificial-heart- finally-ready-for-market-abiomeds-potential-billion-dollar-monopoly/ (accessed August 3, 2010) Zenios, S., J. Makower, P. Yock, T. J. Brinton, U. N. Kumar, L. Denend, and T. M. Krummel. 2010. Biodesign: The Process of Innovating Medical Technologies. New York: Cam- bridge University Press. Zhang, F. R., W. Huang, S. M. Chen, L. D. Sun, H. Liu, Y. Li, Y. Cui, et al. 2009. Genomewide association study of leprosy. New England Journal of Medicine 361(27):2609-2618. Zielinska, E. 2009. Team of rivals. TheScientist.com 23(11):62. Zipes, D. P., P. Libby, R. O. Bonow, and E. Braunwald, eds. 2007. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8 ed. St. Louis, MO: W.B. Saunders. Zlotogora, J. 2009. Population programs for the detection of couples at risk for severe mono- genic genetic diseases. Human Genetics 126(2):247-253.